Elevated plasma pentraxin3 levels and its association with neovascular age-related macular degeneration

Ocular Immunology and Inflammation

Volumn 23, Issue 3, 2015, Pages 205-211

  Min, Jung Kee ^a   Kim, Jaehong ^b   Woo, Je Moon ^a  

^a Ulsan University College of Medicine   (South Korea)

^b Gachon University College of Medicine   (South Korea)

Author keywords

Age related macular degeneration; Biomarker; C reactive protein; Inflammation; Pentraxin3

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; PENTRAXIN 3; ACUTE PHASE PROTEIN; SERUM AMYLOID P;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ELISA KIT; FEMALE; HUMAN; MALE; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; PATHOGENESIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; BLOOD; CHOROIDAL NEOVASCULARIZATION; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; INFLAMMATION; MACULAR DEGENERATION; METABOLISM; MIDDLE AGED; VERY ELDERLY;

ACUTE-PHASE PROTEINS; AGED; AGED, 80 AND OVER; BIOMARKERS; C-REACTIVE PROTEIN; CHOROIDAL NEOVASCULARIZATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; HUMANS; INFLAMMATION; MACULAR DEGENERATION; MALE; MIDDLE AGED; SERUM AMYLOID P-COMPONENT;

EID: 84931049825     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2014.891755     Document Type: Article

References (72)

1. Evans JR. Risk factors for age-related macular degeneration. Prog Retin Eye Res. 2001; 20: 227-253
2. Vine AK, Stader J, Branham K, et al. Biomarkers of cardiovascular disease as risk factors for age-related macular degeneration. Ophthalmology. 2005; 112: 2076-2080
3. Maller J, George S, Purcell S, et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet. 2006; 38: 1055-1059
4. Seitsonen SP, Onkamo P, Peng G, et al. Multifactor effects and evidence of potential interaction between complement factor H Y402H and LOC387715 A69S in age-related macular degeneration. PLoS ONE. 2008; 3: e3833
5. Sobrin L, Reynolds R, Yu Y, et al. ARMS2/HTRA1 locus can confer differential susceptibility to the advanced subtypes of age-related macular degeneration. Am J Ophthalmol. 2011; 151: 345-352
6. Yuan D, Yang Q, Liu X, et al. Complement factor H Val62lle variant and risk of age-related macular degeneration: a meta-Analysis. Mol Vis. 2013; 19: 374-383
7. Seddon JM, Willett WC, Speizer FE, Hankinson SE. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA. 1996; 276: 1141-1146
8. Seddon JM, Cote J, Davis N, Rosner B. Progression of agerelated macular degeneration: association with body mass index, wrist circumference, and waist-hip ratio. Arch Ophthalmol. 2003; 121: 785-792
9. SmithW, Mitchell P, Leeder SR, Wang JJ. Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountain Eye Study. Arch Ophthalmol. 1998; 116: 583-587
10. Seddon JM, Gensler G, Milton RC, et al. Association between C-reactive protein and age-related macular degeneration. JAMA. 2004; 291: 704-710
11. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001; 285: 2481-2485
12. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107: 363-369
13. Manfredi AA, Rovere-Querini P, Bottazzi B, et al. Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol. 2008; 20: 538-544
14. Kikuchi M, Nakamura M, Ishikawa K, et al. Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration. Ophthalmology. 2007; 114: 1722-1727
15. Alles VV, Bottazzi B, Peri G, et al. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood. 1994; 84: 3483-3493
16. Breviario F, d'Aniello EM, Golay J, et al. Interleukin-1- inducible genes in endothelial cells: cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem. 1992; 267: 22190-22197
17. Doni A, Peri G, Chieppa M, et al. Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur J Immunol. 2003; 33: 2886-2893
18. Han B, Mura M, Andrade CF, et al. TNFa-induced long pentraxin PTX3 expression in human lung epithelial cells via JNK. J Immunol. 2005; 175: 8303-8311
19. Lee GW, Lee TH, Vilcek J. TSG-14, a tumor necrosis factorand IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J Immunol. 1993; 150: 1804-1812
20. Perrier P, Martinez FO, Locati M, et al. Distinct transcriptional programs activated by interleukin-10 with or without lipopolysaccharide in dendritic cells: induction of the B cell-Activating chemokine, CXC chemokine ligand 13. J Immunol. 2004; 172: 7031-7042
21. Deban L, Jarva H, Lehtinen MJ, et al. Binding of the long pentraxin PTX3 to Factor H: interacting domains and function in the regulation of complement activation. J Immunol. 2008; 181: 8433-8440
22. Bottazzi B, Vouret-Craviari V, Bastone A, et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem. 1997; 272: 32817-32823
23. Garlanda C, Hirsch E, Bozza S, et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature. 2002; 420: 182-186
24. Nauta AJ, Bottazzi B, Mantovani A, et al. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol. 2003; 33: 465-473
25. Salustri A, Garlanda C, Hirsch E, et al. PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in vivo fertilization. Development. 2004; 131: 1577-1586
26. Diniz SN, Nomizo R, Cisalpino PS, et al. PTX3 function as an opsonin for the dectin-1-dependent internalization of zymosan by macrophages. J Leukoc Biol. 2004; 75: 649-56
27. Jeannin P, Bottazzi B, Sironi M, et al. Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. Immunity. 2005; 22: 551-60
28. Rovere P, Peri G, Fazzini F, et al. The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood. 2000; 96: 4300-4306
29. Dias AA, Goodman AR, Dos Santos JL, et al. TSG-14 transgenic mice have improved survival to endotoxemia and to CLP-induced sepsis. J Leukoc Biol. 2001; 69: 928-936
30. Baruah P, Dumitriu IE, Peri G, et al. The tissue pentraxin PTX3 limits C1q-mediated complement activation and phagocytosis of apoptotic cells by dendritic cells. J Leukoc Biol. 2006; 80: 87-95
31. Mantovani A, Valentino S, Gentile S, et al. The long pentraxin PTX3: a paradigm for humoral pattern recognition molecules. Ann N Y Acad Sci. 2013 doi: 10.1111/nyas. 12043. Epub 2013 Mar 25
32. Norata GD, Marchesi P, Pulakazhi Venu VK, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation. 2009; 120: 699-708
33. Salio M, Chimenti S, De Angelis N, et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2008; 117: 1055-1064
34. Inoue K, Sugiyama A, Reid PC, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol. 2007; 27: 161-167
35. Lee DH, Jeon HK, You JH, et al. Pentraxin3 as a novel marker predicting congestive heart failure in subjects with acute coronary syndrome. Korean Circ J. 2010; 40: 370-376
36. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995; 39: 367-374
37. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006; 113: 633.e1-4
38. Alberti L, Gilardini L, Zulian A, et al. Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis. 2009; 202: 455-460
39. Yilmaz MI, Axelsson J, Sonmez A, et al. Effect of renin angiotensin system blockade on pentraxin3 levels in type-2 diabetic patients with proteinuria. Clin J Am Soc Nephrol. 2009; 4: 535-541
40. Ohbayashi H, Miyazawa C, Miyamoto K, et al. Pitavastatin improves plasma pentraxin3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. J Atheroscler Thromb. 2009; 16: 490-500
41. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res. 2001; 20: 385-414
42. Hageman GS, Luthert PJ, Victor Chong NH, et al. An integrated hypothesis that considers drusen as biomarker of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001; 20: 705-732
43. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002; 134: 411-431
44. Seddon JM, George S, Rosner B, Rifai N. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol. 2005; 123: 774-782
45. Dasch B, Fuhs A, Behrens T, et al. Inflammatory markers in age-related maculopathy: cross-sectional analysis from the Muenster Aging and Retina Study. Arch Ophthalmol. 2005; 123: 1501-1506
46. Seddon JM, Gensler G, Klein ML, Milton RC. C-reactive protein and homocysteine are associated with dietary and behavioral risk factors for age-related macular degeneration. Nutrition. 2006; 22: 441-443
47. Seddon JM, Gensler G, Klein ML, Milton RC. Evaluation of plasma homocysteine and risk of age-related macular degeneration. Am J Ophthalmol. 2006; 141: 201-203
48. Reynolds R, Hartnett ME, Atkinson JP, et al. Plasma complement components and activation fragments: associations with age-related macular degeneration genotype and phenotypes. Invest Ophthalmol Vis Sci. 2009; 50: 5818-5827
49. Scholl HP, Charbel Issa P, Walier M, et al. Systemic complement activation in age-related macular degeneration. PLoS One. 2008; 3: e2593
50. Smailhodzic D, Klaver CC, Klevering BJ, et al. Risk alleles in CFH and ARMS2 are independently associated with systemic complement activation in age-related macular degeneration. Ophthalmology. 2012; 119: 339-346
51. Cousins SW, Espinosa-Heidmann DG, Csaky KG. Monocyte activation in patients with age-related macular degeneration: a biomarker of risk of choroidal neovascularization?. Arch Ophthalmol. 2004; 124: 1013-1018
52. Javadzadeh A, Ghorbanihaghjo A, Bahreini E, et al. Plasma oxidized LDL and thiol-containing molecules in patients with exudative age-related macular degeneration. Mol Vis. 2010; 16: 2578-2584
53. Wang JJ, Rochtchinia E, Lee AJ, et al. Ten-year incidence and progression of age-related maculopathy: the Bule Mountains Eye Study. Ophthalmol. 2007; 114: 92-98
54. Kamei M, Yoneda K, Kume N, et al. Scavenger receptors for oxidized lipoprotein in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2007; 48: 1801-1807
55. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005; 23: 337-366
56. Rolph MS, Zimmer S, Bottazzi B, et al. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2002; 22: e10-14
57. Savchenko A, Imamura M, Ohashi R, et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol. 2008; 215: 48-55
58. Jaillon S, Peri G, Delneste Y, et al. The humoral pattern recognition receptor PTX3 is stored in neurotphil granules and localizes in extracellular traps. J Exp Med. 2007; 204: 793-804
59. Woo JM, Kwon MY, Shin DY, et al. Human retinal pigment epithelial cells express the long pentraxin PTX3. Mol Vis. 2013; 19: 303-310
60. Fujimoto T, Sonoda KH, Hijioka K, et al. Choroidal neovascularization enhanced by Chlamydia pneumoniae via Toll-like receptor 2 in the retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2010; 51: 4694-4702
61. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001; 2: 675-680
62. Maloney SC, Antecka E, Orellana ME, et al. Choroidal neovascular membranes express toll-like receptor 3. Ophthalmic Res. 2010; 44: 237-241
63. Pangburn MK, Muller-Eberhard HJ. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med. 1980; 152: 1102-1114
64. Pangburn MK, Muller-Eberhard HJ. The alternative pathway of complement. Springer Semin Immunopathol. 1984; 7: 163-192
65. Weiler JM, Daha MR, Austen KF, Fearon DT. Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci USA. 1976; 73: 3268-3272
66. Whaley K, Ruddy S. Modulation of the alternative complement pathways by beta 1H globulin. J Exp Med. 1976; 144: 1147-1163
67. Pangburn MK, Schreiber RD, Muller-Eberhard HJ. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med. 1977; 146: 257-270
68. Meri S, Pangburn MK. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci USA. 1990; 87: 3982-3986
69. Morgan BP, Meri S. Membrane proteins that protect against complement lysis. Springer Semin Immunopathol. 1994; 15: 369-396
70. Zipfel PF, Heinen S, Jó zsi M, Skerka C. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol. 2006; 43: 97-106
71. Laine M, Jarva H, Seitsonen S, et al. Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol. 2007; 178: 3831-3836
72. Kume N, Mitsuoka H, Hayashida K, Tanaka M. Pentraxin 3 as a biomarker for acute coronary syndrome: Comparison with biomarkers for cardiac damage. J Cardiol. 2011; 58: 34-45